Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ignacio Gil

Showing results (121-130 of 144) with videos related to

Pageof 15
Sort By:
Cancer Treatment Reviews|June 24, 2014
Novel therapeutic strategies for patients with NSCLC that do not respond to treatment with EGFR inhibitorsChristian Rolfo, Elisa Giovannetti, David S Hong, et al.
Thorax|November 26, 2018
5 protein-based signature for resectable lung squamous cell carcinoma improves the prognostic performance of the TNM stagingElena Martínez-Terroba, Carmen Behrens, Jackeline Agorreta, et al.
Clinical Chemistry and Laboratory Medicine|July 7, 2020
Performance comparison of two next-generation sequencing panels to detect actionable mutations in cell-free DNA in cancer patientsMónica Macías, Eva Cañada-Higueras, Estibaliz Alegre, et al.
Computers in Biology and Medicine|January 30, 2026
Influence of CT harmonization in longitudinal radiomics for NSCLC immunotherapy response predictionBenito Farina, Gonzalo Vegas-Sánchez-Ferrero, Ana Delia Ramos-Guerra, et al.
Journal of Translational Medicine|March 5, 2023
Integration of longitudinal deep-radiomics and clinical data improves the prediction of durable benefits to anti-PD-1/PD-L1 immunotherapy in advanced NSCLC patientsBenito Farina, Ana Delia Ramos Guerra, David Bermejo-Peláez, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 26, 2025
Preventing Infusion-Related Reactions With Intravenous Amivantamab-Results From SKIPPirr, a Phase 2 Study: A Brief ReportAlexander I Spira, Luis Paz-Ares, Ji-Youn Han, et al.
Clinical and Experimental Medicine|August 6, 2024
Extracellular vesicles miR-574-5p and miR-181a-5p as prognostic markers in NSCLC patients treated with nivolumabCarlo Genova, Silvia Marconi, Giovanna Chiorino, et al.
Cancers|October 31, 2020
Id1 and PD-1 Combined Blockade Impairs Tumor Growth and Survival of <i>KRAS</i>-mutant Lung Cancer by Stimulating PD-L1 Expression and Tumor Infiltrating CD8<sup>+</sup> T CellsIosune Baraibar, Marta Roman, María Rodríguez-Remírez, et al.
Nature Cancer|February 5, 2022
Short-term starvation reduces IGF-1 levels to sensitize lung tumors to PD-1 immune checkpoint blockadeDaniel Ajona, Sergio Ortiz-Espinosa, Teresa Lozano, et al.
Acta Neuropathologica Communications|June 28, 2025
Impaired splicing machinery in craniopharyngiomas unveils PRPF8 and RAVER1 as novel biomarkers and therapeutic targetsAntonio C Fuentes-Fayos, Miguel E G-García, Teresa Sánchez-Medianero, et al.
Pageof 15

Showing results (121-130 of 144) with videos related to

Sort By:
Pageof 15
Cancer Treatment Reviews|June 24, 2014
Novel therapeutic strategies for patients with NSCLC that do not respond to treatment with EGFR inhibitorsChristian Rolfo, Elisa Giovannetti, David S Hong, et al.
Thorax|November 26, 2018
5 protein-based signature for resectable lung squamous cell carcinoma improves the prognostic performance of the TNM stagingElena Martínez-Terroba, Carmen Behrens, Jackeline Agorreta, et al.
Clinical Chemistry and Laboratory Medicine|July 7, 2020
Performance comparison of two next-generation sequencing panels to detect actionable mutations in cell-free DNA in cancer patientsMónica Macías, Eva Cañada-Higueras, Estibaliz Alegre, et al.
Computers in Biology and Medicine|January 30, 2026
Influence of CT harmonization in longitudinal radiomics for NSCLC immunotherapy response predictionBenito Farina, Gonzalo Vegas-Sánchez-Ferrero, Ana Delia Ramos-Guerra, et al.
Journal of Translational Medicine|March 5, 2023
Integration of longitudinal deep-radiomics and clinical data improves the prediction of durable benefits to anti-PD-1/PD-L1 immunotherapy in advanced NSCLC patientsBenito Farina, Ana Delia Ramos Guerra, David Bermejo-Peláez, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 26, 2025
Preventing Infusion-Related Reactions With Intravenous Amivantamab-Results From SKIPPirr, a Phase 2 Study: A Brief ReportAlexander I Spira, Luis Paz-Ares, Ji-Youn Han, et al.
Clinical and Experimental Medicine|August 6, 2024
Extracellular vesicles miR-574-5p and miR-181a-5p as prognostic markers in NSCLC patients treated with nivolumabCarlo Genova, Silvia Marconi, Giovanna Chiorino, et al.
Cancers|October 31, 2020
Id1 and PD-1 Combined Blockade Impairs Tumor Growth and Survival of <i>KRAS</i>-mutant Lung Cancer by Stimulating PD-L1 Expression and Tumor Infiltrating CD8<sup>+</sup> T CellsIosune Baraibar, Marta Roman, María Rodríguez-Remírez, et al.
Nature Cancer|February 5, 2022
Short-term starvation reduces IGF-1 levels to sensitize lung tumors to PD-1 immune checkpoint blockadeDaniel Ajona, Sergio Ortiz-Espinosa, Teresa Lozano, et al.
Acta Neuropathologica Communications|June 28, 2025
Impaired splicing machinery in craniopharyngiomas unveils PRPF8 and RAVER1 as novel biomarkers and therapeutic targetsAntonio C Fuentes-Fayos, Miguel E G-García, Teresa Sánchez-Medianero, et al.
Pageof 15